A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Erdafitinib (Primary) ; Metformin; Midazolam
- Indications Carcinoma; Urogenital cancer
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 17 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 01 Oct 2024 Results assessing effect of erdafitinib on the pharmacokinetics of midazolam and metformin assessing published in the Clinical Pharmacology in Drug Development
- 06 May 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.